Note: Any agenda items discussed by the DUR/P&T Committee may result in changes to utilization control recommendations to the OHA. Timing, sequence and inclusion of agenda items presented to the Committee may change at the discretion of the OHA, P&T Committee and staff. The DUR/P&T Committee functions as the Rules Advisory Committee to the Oregon Health Plan for adoption into Oregon Administrative Rules 410-121-0030 & 410-121-0040 in accordance with Oregon Revised Statute 183.333.

I. CALL TO ORDER

1:00 PM  A. Roll Call & Introductions       R. Citron (OSU)
          B. Conflict of Interest Declaration  R. Citron (OSU)
          C. Approval of Agenda and Minutes    R. Citron (OSU)
          D. Department Update                  T. Douglass (OHA)

1:15 PM  II. CONSENT AGENDA TOPICS          J. Slater (Chair)
          A. Orphan Drug Policy Update
          B. Oncology Policy Update
              1. Public Comment

III. PREFERRED DRUG LIST NEW BUSINESS

1:20 PM  A. Parkinson’s Disease Class Update with New Drug Evaluations    A. Gibler (OSU)
       1. Class Update/Prior Authorization Criteria
       3. Ongentys® (opicapone) New Drug Evaluation
       5. Public Comment
       6. Discussion of Clinical Recommendations to OHA

1:40 PM  B. Asthma/COPD Class Update       K. Sentena (OSU)
       1. Class Update/Prior Authorization Criteria
       2. Public Comment
       3. Discussion of Clinical Recommendations to OHA

2:00 PM  C. Antiepileptics (non-injectable) Class Update and New Drug Evaluation  D. Moretz (OSU)
       1. Class Update/Prior Authorization Criteria
       2. Fintepla® (fenfluramine) New Drug Evaluation
       3. Public Comment
4. Discussion of Clinical Recommendations to OHA

2:15 PM  
D. Antacids (Proton Pump Inhibitors and H2 Receptor Antagonists)  
Class Update  
1. Class Update/Prior Authorization Criteria  
2. Public Comment  
3. Discussion of Clinical Recommendations to OHA  
K. Sentena (OSU)

2:30 PM  
E. Atopic Dermatitis Literature Scan  
1. Literature Scan/Prior Authorization Criteria  
2. Public Comment  
3. Discussion of Clinical Recommendations to OHA  
D. Moretz (OSU)

2:45 PM  
F. Biologics for Autoimmune Conditions DERP Summary and Policy Evaluation  
1. DERP Summary  
2. Policy Evaluation  
3. Public Comment  
4. Discussion of Clinical Recommendations to OHA  
D. Moretz (OSU)  
S. Servid (OSU)

3:05 PM  
BREAK

IV. DUR NEW BUSINESS

3:20 PM  
A. Bipolar Drug Use Evaluation  
1. Mental Health Clinical Advisory Group Algorithms  
2. Drug Use Evaluation  
3. Public Comment  
4. Discussion of Clinical Recommendations to OHA  
D. Nagarkatti-Gude & N. Kashey (MHCAG)  
S. Servid (OSU)

3:35 PM  
B. Drug Discontinuation Case Management Policy Proposal  
1. Policy Proposal  
2. Public Comment  
3. Discussion of Clinical Recommendations to OHA  
S. Servid (OSU)

3:50 PM  
C. Consultation for Antipsychotics in Kids Policy Evaluation  
1. Policy Evaluation  
2. Public Comment  
3. Discussion of Clinical Recommendations to OHA  
S. Servid (OSU)

4:05 PM  
D. Modafinil/armodafinil Drug Use Evaluation  
1. Drug Use Evaluation/Safety Edit  
2. Public Comment  
3. Discussion of Clinical Recommendations to OHA  
D. Engen (OSU)

4:20 PM  
V. EXECUTIVE SESSION
4:50 PM VI. RECONVENE for PUBLIC RECOMMENDATIONS

VII. ADJOURN